First steps in peptide science

Schwyzer, Robert

doi:10.1002/pro.5560051123

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The preparation of synthetic peptides like oxytocin, vasopressin, angiotensins, was a difficult and time consuming accomplishment (Schwyzer, 1996; Ragnarsson, 2007) until the introduction of solid phase peptide synthesis, which automated the synthetic process (Merrifield, 1963), thus allowing the routine high‐throughput synthesis of peptides, large polypeptides and small proteins in the range of 30–100 amino acid residues (Loffet, 2002). In parallel, combinatorial chemistry resulted in the synthesis of highly diverse peptide libraries, incorporating various chemical elements, groups, cofactors, metal atoms in the peptide or protein structures (Hruby, 2005; Sato et al, 2006; Watt, 2006).…”

Section: Introductionmentioning

confidence: 99%

Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

Katsila

Siskos

Tamvakopoulos

2011

Mass Spectrom. Rev.

View full text Add to dashboard Cite

Peptide and protein drugs have evolved in recent years into mainstream therapeutics, representing a significant portion of the pharmaceutical market. Peptides and proteins exhibit highly diverse structures, broad biological activities as hormones, neurotransmitters, structural proteins, metabolic modulators and therefore have a significant role as both therapeutics and biomarkers. Understanding the metabolism of synthetic or biotechnologically derived peptide and protein drugs is critical for pharmaceutical development as metabolism has a significant impact on drug efficacy and safety. Although the same principles of pharmacokinetics and metabolism of small molecule drugs apply to peptide and protein drugs, there are few notable differences. Moreover, the study of peptide and protein drug metabolism is a rather complicated process which requires sophisticated analytical techniques, and mass spectrometry based approaches have provided the capabilities for efficient and reliable quantification, characterization, and metabolite identification. This review article will focus on the current use of mass spectrometry for the study of the metabolism of peptide and protein drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

Katsila

Siskos

Tamvakopoulos

2011

Mass Spectrom. Rev.

View full text Add to dashboard Cite

show abstract

“…While dealing with these questions it is important to bare in mind that what we call the 'bioactive conformation' can principally be an energetically unfavorable conformation. The increase in the free energy of such a ligand has to be compensated by favorable interactions with the host molecule (1).…”

mentioning

confidence: 99%

Structure-activity relationship of the ring portion in backbone-cyclic C-terminal hexapeptide analogs of substance P. NMR and molecular dynamics

Behrens

Mathä

Bitan

et al. 2009

International Journal of Peptide and Protein Research

View full text Add to dashboard Cite

The conformations of two backbone‐cyclized substance P analogs were derived from homo‐ and heteronuclear NMR measurements and molecular dynamics simulations carried out in DMSO. The analogs contain subtle variations in the ring chemistry and are compared with biologically active analogs previously examined. The correlation between conformation and activity is used to gain insight into the conformational requirements from the pharmacophore.

show abstract

“…Ηζημνζηά, ημ πνχημ ζοκεεηζηυ πεπηίδζμ έθααε πχνα απυ ημκ E. Fischer, ηαηά πνμζέββζζδ, έκακ αζχκα πνζκ. Δκημφημζξ, δ θανιαηεοηζηή πνήζδ ηςκ ζοκεεηζηχκ πεπηζδίςκ ζοκακηάηαζ ιυθζξ ιεηά ημ πέναξ ημο Β παβημζιίμο πμθέιμο, υηακ μζ μιάδεξ ηςκ R. Schwyzer (Ciba), Huguenin (Sandoz) ηαζ du Vigneaud παναζηεφαζακ πεπηίδζα (ςηοημηίκδ, ααγμπνεζίκδ ηαζ αββεζμηεκζίκεξ) ζε ηαεανή ιμνθή (DuVigneaud, 1954;Schwyzer, 1996;Ragnarsson, 2007). Αξ ζδιεζςεεί πςξ δ πεπηζδζηή ζφκεεζδ ήηακ ιζα ελαζνεηζηά απαζηδηζηή ηαζ πνμκμαυνα δζαδζηαζία ..έςξ ημ 1963.…”

Section: Introductionunclassified

In vivo βιολογική αξιολόγηση και φαρμακοκινητική μελέτη με χρήση HPLC-MS-MS του Leuprolide και αναλόγων του που εμπλέκονται στη θεραπεία του καρκίνου

Κατσίλα¹

View full text Add to dashboard Cite

Ημκζζιυξ απυ δθεηηνζηυ πεδίμ ιε ρεηαζιυ 2.3.3. Δίδδ ακαθοηχκ Σεηναπμθζηυξ ακαθοηήξ Σεηναπμθζηή παβίδα ζυκηςκ 2.3.4. Ακζπκεοηήξ 2.4. Applied Biosystems/ MDS Sciex 4000 QTrap TM LC -MS/ MS system 2.5. ΣΔΥΝΗΚΔ ΑΝΑΛΤΖ ΣΖ ΦΑΜΑΣΟΜΔΣΡΗΑ ΜΑΕΑ 2.5.1. Σεπκζηή πθήνμοξ ζάνςζδξ 2.5.2. Σεπκζηή επζθεηηζηήξ παναημθμφεδζδξ ζυκηςκ 2.5.3. Σεπκζηή δίδοιδξ θαζιαημιεηνίαξ ιάγαξ Σεπκζηή ζάνςζδξ πανάβςβμο ζυκημξ Σεπκζηή επζθεηηζηήξ παναημθμφεδζδξ πμθθαπθχκ ακηζδνάζεςκ εναοζιάηςζδξ ζυκηςκ ΚΔΦ.

show abstract

First steps in peptide science

Cited by 3 publications

References 0 publications

Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

Structure-activity relationship of the ring portion in backbone-cyclic C-terminal hexapeptide analogs of substance P. NMR and molecular dynamics

In vivo βιολογική αξιολόγηση και φαρμακοκινητική μελέτη με χρήση HPLC-MS-MS του Leuprolide και αναλόγων του που εμπλέκονται στη θεραπεία του καρκίνου

Contact Info

Product

Resources

About